Royalty Pharma RPRX Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $586.4M-46.1% | $618.7M-33.4% | $938.94M-1.2% | $631.91M-64.2% | $1.09B+29.0% | ||
| $21.9M+81.0% | $18.8M-67.7% | $16.1M-66.8% | $13.2M-65.7% | $12.1M-58.3% | ||
| $20.04B+3.3% | $20.46B+2,511% | $20.09B+3.8% | $19.44B+5.0% | $19.41B+9.2% | ||
| $10.16M+230% | $6.89M+64.6% | $5.52M+11.1% | $4.45M+94.2% | $3.08M-38.5% | ||
| $1.43B-22.6% | $1.53B-15.2% | $1.85B+3.1% | $1.52B-41.1% | $1.84B+18.2% | ||
| $924.63M— | $924.63M— | $924.63M— | $924.63M— | —— | ||
| $16.54B+10.0% | $16.21B+7.1% | $15.76B+5.3% | $15.13B+9.0% | $15.03B+11.6% | ||
| $265.7M-21.0% | $289.97M-23.6% | $290.96M-17.1% | $275.91M-21.6% | $336.21M-4.0% | ||
| $406.8M+85.8% | $419M-39.6% | $302.5M-54.0% | $271.9M-56.8% | $219M-53.8% | ||
| $173.27M+22.8% | $171.31M-8.4% | $129.39M-43.5% | $110.53M-37.9% | $141.08M-49.1% | ||
| $17.32B+10.0% | $17.06B+7.2% | $16.62B+5.7% | $15.98B+9.1% | $15.75B+11.5% | ||
| $19.82B+12.5% | $19.62B+7.7% | $19.35B+7.2% | $18.32B+3.8% | $17.61B+9.2% | ||
| $25.48M-32.3% | $19.4M+45.1% | $41.42M+87.8% | $20.21M-13.7% | $37.63M+226% | ||
| $17.48M-6.0% | $53.16M-22.5% | $3.12M-90.0% | $3.08M-96.8% | $18.6M+106% | ||
| $380M-61.9% | $380M-61.9% | $380M-61.9% | $999.44M— | $998.61M— | ||
| $18.49M— | $19.26M— | $20.02M— | $20.77M— | —— | ||
| $25.3M+31.6% | $110.82M+13.0% | $29.04M-24.4% | $85.61M+52.2% | $19.22M+52.6% | ||
| $535.68M-54.7% | $636.21M-49.2% | $530.8M-54.5% | $1.21B+338% | $1.18B+850% | ||
| $8.58B+29.6% | $8.57B+29.6% | $8.57B+29.6% | $7B-7.9% | $6.62B+7.8% | ||
| $18.49M— | $19.26M— | $20.02M— | $20.77M— | —— | ||
| $117.79M+558% | $120.84M+900% | $126.94M+2,175% | $143.33M+430% | $17.9M+456% | ||
| $9.88B+26.3% | $9.91B+25.7% | $9.73B+25.0% | $8.82B+11.6% | $7.82B+24.8% | ||
| $4.38B+4.1% | $4.12B+0.5% | $4.11B+0.1% | $4.13B+0.7% | $4.21B+3.3% | ||
| $2.51B+1.1% | $2.36B-17.2% | $2.3B-16.7% | $2.22B-6.5% | $2.48B+2.2% | ||
| $2.71M+2.1% | $2.61M-1.9% | $2.61M-1.7% | $2.61M-1.8% | $2.65M0.0% | ||
| $3.05B-1.7% | $3.24B-4.6% | $3.21B-5.4% | $3.16B-3.7% | $3.1B-7.8% | ||
| $9.94B+1.6% | $9.71B-6.1% | $9.62B-6.2% | $9.5B-2.6% | $9.78B-0.9% | ||
| $19.82B+12.5% | $19.62B+7.7% | $19.35B+7.2% | $18.32B+3.8% | $17.61B+9.2% | ||
| $2.72B-25.7% | $3.4B-10.3% | $3.47B-4.3% | $3.46B-10.4% | $3.66B+0.4% | ||
| $21.9M+81.0% | $18.8M-67.7% | $16.1M-66.8% | $13.2M-65.7% | $12.1M-58.3% | ||
| $10.16M+230% | $6.89M+64.6% | $5.52M+11.1% | $4.45M+94.2% | $3.08M-38.5% | ||
| $27.51M+15.7% | $29.32M+8.8% | $28.9M+16.1% | $27.74M+17.7% | $23.79M+7.0% | ||
| $20.04B+3.3% | $20.46B+3.9% | $20.09B+3.8% | $19.44B+5.0% | $19.41B+9.2% | ||
| $779.84M+8.8% | $854.39M+9.0% | $860.07M+12.3% | $842.94M+12.4% | $716.56M+8.5% | ||
| $17.32B+10.0% | $17.06B+7.2% | $16.62B+5.7% | $15.98B+9.1% | $15.75B+11.5% | ||
| $17.32B+10.0% | $17.06B+7.2% | $16.62B+5.7% | $15.98B+9.1% | $15.75B+11.5% | ||
| $17.32B+10.0% | $17.06B+7.2% | $16.62B+5.7% | $15.98B+9.1% | $15.75B+11.5% | ||
| $76.85M+109% | $79.29M+136% | $86.59M+102% | $85.49M+210% | $36.71M+718% | ||
| $16.54B+10.0% | $16.21B+7.1% | $15.76B+5.3% | $15.13B+9.0% | $15.03B+11.6% | ||
| $173.27M+22.8% | $171.31M-8.4% | $129.39M-43.5% | $110.53M-37.9% | $141.08M-49.1% | ||
| $173.27M+22.8% | $171.31M-8.4% | $129.39M-43.5% | $110.53M-37.9% | $141.08M-49.1% | ||
| $406.8M+85.8% | $419M-39.6% | $302.5M-54.0% | $271.9M-56.8% | $219M-53.8% | ||
| $16.54B+10.0% | $16.21B+7.1% | $15.76B+5.3% | $15.13B+9.0% | $15.03B+11.6% | ||
| $76.85M+109% | $79.29M+136% | $86.59M+102% | $85.49M+210% | $36.71M+718% | ||
| $76.85M+109% | $79.29M+136% | $86.59M+102% | $85.49M+210% | $36.71M+718% | ||
| $25.48M-32.3% | $19.4M+45.1% | $41.42M+87.8% | $20.21M-13.7% | $37.63M+226% | ||
| $87.42M-19.7% | $72.83M-3.9% | $77.22M— | $98.2M— | $108.8M— | ||
| $17.48M-6.0% | $53.16M-22.5% | $3.12M-90.0% | $3.08M-96.8% | $18.6M+106% | ||
| $3.04M— | —— | $1.01M— | $2.02M— | —— | ||
| $3.72M— | —— | $3.78M— | $3.78M— | —— | ||
| $3.76M— | —— | $3.73M— | $3.73M— | —— | ||
| $3.72M— | —— | $3.78M— | $3.78M— | —— | ||
| $3.73M— | —— | $3.72M— | $3.72M— | —— | ||
| $3.76M— | —— | $3.73M— | $3.73M— | —— | ||
| $3.79M— | —— | $4.05M— | $4.05M— | —— | ||
| $21.16M— | —— | $23.17M— | $24.18M— | —— | ||
| $2.67M— | —— | $3.15M— | $3.41M— | —— | ||
| $223.56M+22.5% | $229.08M+22.1% | $234.27M+21.6% | $177.5M-10.3% | $182.55M+13.6% | ||
| $3.73M— | —— | $3.72M— | $3.72M— | —— | ||
| $3.73M— | —— | $3.72M— | $3.72M— | —— | ||
| $3.76M— | —— | $3.73M— | $3.73M— | —— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| —— | —— | —— | $33.12— | —— | ||
| $1.7B-26.1% | —— | $1.9B— | $2B— | $2.3B— | ||
| $1.7B-26.1% | —— | $1.9B— | $2B— | $2.3B— | ||
| $20.04B+3.3% | $20.46B+3.9% | $20.09B+3.8% | $19.44B+5.0% | $19.41B+9.2% | ||
| $648.67M— | $577.87M— | $502.94M— | $467.14M— | —— | ||
| 100%0.0% | —— | 100%0.0% | 100%0.0% | 100%0.0% | ||
| 10.0% | —— | 10.0% | 10.0% | 10.0% | ||
| $223.56M+22.5% | $229.08M+22.1% | $234.27M+21.6% | $177.5M-10.3% | $182.55M+13.6% | ||
| $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | ||
| 427.4M+8.3% | 411.5M+4.9% | 409.9M+5.0% | 409M+4.9% | 394.5M+1.4% | ||
| 427.4M+8.3% | 411.5M+4.9% | 409.9M+5.0% | 409M+4.9% | 394.5M+1.4% | ||
| $265.7M-21.0% | $289.97M-23.6% | $290.96M-17.1% | $275.91M-21.6% | $336.21M-4.0% | ||
| $2.52B-26.8% | $3.19B-10.3% | $3.25B-5.1% | $3.24B-12.2% | $3.44B-2.1% | ||
| $204.91M-8.8% | $211.96M-11.0% | $220.69M+9.4% | $216.71M+29.0% | $224.62M+63.9% | ||
| $17.53B+9.7% | $17.27B+7.0% | $16.84B+5.7% | $16.19B+9.4% | $15.97B+12.0% | ||
| $21.16M— | —— | $23.17M— | $24.18M— | —— | ||
| $3.13M— | —— | $6.88M— | $6.88M— | —— | ||
| $2.67M— | —— | $3.15M— | $3.41M— | —— | ||
| $3.05B-1.7% | $3.24B-4.6% | $3.21B-5.4% | $3.16B-3.7% | $3.1B-7.8% | ||
| 20.0% | —— | 20.0% | 20.0% | 20.0% | ||
| 4+33.3% | —— | 4— | 4— | 3— | ||
| $825M— | —— | —— | —— | —— | ||
| $600M— | —— | —— | —— | —— | ||
| —— | —— | —— | $33.12— | —— | ||
| —— | —— | —— | —— | $3B— | ||
| $1.7B-26.1% | —— | $1.9B— | $2B— | $2.3B— | ||
| $3.04M— | —— | $1.01M— | $2.02M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Royalty Pharma's total assets?
- Royalty Pharma (RPRX) holds $19.8B in total assets, up 12.5% year over year.
- How much debt does Royalty Pharma have?
- Royalty Pharma carries $9.0B in total debt against $9.9B of shareholders' equity, a debt-to-equity ratio of 0.90.
- How much cash does Royalty Pharma have?
- Royalty Pharma holds $586.4M in cash and equivalents.
- Can Royalty Pharma cover its short-term obligations?
- Its current ratio is 2.66 — current assets exceed current liabilities.
- Where does Royalty Pharma's balance sheet data come from?
- Every line is extracted from Royalty Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
